RO7296682

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Solid Tumors

Phase 1

A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

TerminatedNCT04158583

Hoffmann-La RocheSolid Tumors

Start: 2019-12-09End: 2022-07-21Updated: 2024-03-04

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

TerminatedNCT04642365

Hoffmann-La RocheSolid Tumors

Start: 2021-01-04End: 2024-01-04Updated: 2025-05-21

Related Papers

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

Cancer Research Communications2025-02-219 citations

Abstract CT176: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors

Cancer Research2023-04-142 citations

Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors

Cancer Research2023-04-142 citations

CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

Blood2022-11-15

Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control

Cancer Research2020-08-154 citations